Sabby Management’s Atossa Therapeutics ATOS Stock Holding History

Sabby Management’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,381	Closed	-$47.6K	–	93
2023 Q1	$47.6K	Sell	4,381 -9,217	-68%	-$103K	0.04%	73
2022 Q4	$108K	Sell	13,598 -13,862	-50%	-$159K	0.09%	67
2022 Q3	$343K	Sell	27,460 -7,527	-22%	-$109K	0.43%	49
2022 Q2	$572K	Buy	34,987 +10,849	+45%	+$171K	0.39%	45
2022 Q1	$453K	Buy	+24,138	New	+$490K	0.07%	64
2021 Q3	–	Sell	-69,732	Closed	-$4.06M	–	183
2021 Q2	$6.61M	Buy	69,732 +53,583	+332%	+$2.84M	0.93%	12
2021 Q1	$511K	Buy	+16,149	New	+$590K	0.1%	110
2019 Q1	–	Sell	-33,497	Closed	-$513K	–	86
2018 Q4	$513K	Buy	33,497 +2,494	+8%	+$49.3K	0.11%	51
2018 Q3	$814K	Buy	31,003 +8,286	+36%	+$271K	0.1%	61
2018 Q2	$750K	Buy	+22,717	New	+$1.22M	0.12%	70
2017 Q3	–	Sell	-1,617	Closed	-$150K	–	171
2017 Q2	$150K	Buy	+1,617	New	+$166K	0.01%	187

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sabby Management's ATOS Position: Q2 2023 in Review

Sabby Management sold out of Atossa Therapeutics (ATOS) in Q2 2023, closing a stake of 4,381 shares — an estimated $47.6K sold.

Sabby Management first reported a position in ATOS in Q2 2017 and held it in 11 quarters. The position peaked at $6.61M in Q2 2021. 52 funds tracked by Wall St. Rank hold ATOS as of Q2 2023.

Sabby Management reported no remaining Atossa Therapeutics position as of Q2 2023 after selling out during the quarter.
Sabby Management sold 4,381 Atossa Therapeutics shares in Q2 2023, an estimated $47.6K.
Sabby Management first reported a position in Atossa Therapeutics in Q2 2017 and held it in 11 quarters.
Sabby Management's Atossa Therapeutics position peaked at $6.61M in Q2 2021.
52 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2023.

Based on Sabby Management's 13F filing for Q2 2023, filed 14 Aug 2023.